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Altered Connexin 43 Expression Underlies Age-Dependent
Decrease of Regulatory T Cell Suppressor Function in
Nonobese Diabetic Mice
Michal Kuczma,* Cong-Yi Wang,*,† Leszek Ignatowicz,* Robert Gourdie,‡ and
Piotr Kraj*
Type 1 diabetes is one of the most extensively studied autoimmune diseases, but the cellular and molecular mechanisms leading to
T cell–mediated destruction of insulin-producing b cells are still not well understood. In this study, we show that regulatory T cells
(Tregs) in NOD mice undergo age-dependent loss of suppressor functions exacerbated by the decreased ability of activated effector
T cells to upregulate Foxp3 and generate Tregs in the peripheral organs. This age-dependent loss is associated with reduced
intercellular communication mediated by gap junctions, which is caused by impaired upregulation and decreased expression of
connexin 43. Regulatory functions can be corrected, even in T cells isolated from aged, diabetic mice, by a synergistic activity of
retinoic acid, TGF-b, and IL-2, which enhance connexin 43 and Foxp3 expression in Tregs and restore the ability of conventional
CD4+ T cells to upregulate Foxp3 and generate peripherally derived Tregs. Moreover, we demonstrate that suppression mediated
by Tregs from diabetic mice is enhanced by a novel reagent, which facilitates gap junction aggregation. In summary, our report
identifies gap junction–mediated intercellular communication as an important component of the Treg suppression mechanism
compromised in NOD mice and suggests how Treg mediated immune regulation can be improved. The Journal of Immunology,
2015, 194: 5261–5271.
T
ype 1 diabetes (T1D) is a complex autoimmune disease
resulting from destruction of pancreatic b-islets by infil-
trating immune cells (1). Both environmental and genetic
factors contribute to the development of the disease in humans and
in NOD mice, which constitute an animal model of diabetes (2).
Cellular mechanisms implicated in the progression of T1D include
aberrant activation of autoreactive T cells, inefficient peripheral
tolerance, and impaired function of immunoregulatory cells, es-
pecially CD4+ regulatory T cells (Tregs) expressing the transcrip-
tion factor Foxp3 (1, 3).
Tregs regulate homeostasis of the immune system and a variety
of immune responses, including autoimmunity, and rely on nu-
merous mechanisms that involve soluble, immunomodulatory
cytokines, IL-10 and TGF-b, as well as membrane molecules and
cell contact–dependent interactions (4, 5). Tregs may also sustain
tolerance by converting effector CD4+ T cells into Tregs. This
mechanism of “infectious” tolerance relies on genetic repro-
gramming of effector cells to become Tregs and involves intercel-
lular transport of cAMP (6, 7). The determinants of which
suppression mechanisms are used in particular immune contexts
remain poorly understood.
Two major subsets of Tregs, thymus-derived (tTreg) and pe-
ripherally derived Tregs (pTreg), were defined based on whether
their suppressor function is acquired during normal thymic T cell
development or after antigenic stimulation in peripheral lym-
phoid organs (8). In vitro–induced Tregs (iTregs) may be generated
by stimulation of CD4+ T cells in the presence of TGF-b and
IL-2 (5). In vivo pTregs are induced by a specialized population
of dendritic cells in a process dependent on TGF-b and retinoic
acid (RA) (9). Treatment of NOD mice with RA delayed the
development of diabetes by inducing and expanding Tregs, and by
protecting islets from immune system–mediated destruction (10, 11).
Several lines of evidence directly showed that Tregs regulate
autoimmunity in diabetes. Transfer of pTregs or iTregs into NOD
mice, or in vivo induction of Tregs, can protect NOD mice from
diabetes (12–14). Conversely, compromised function of Tregs was
found to induce or exacerbate diabetes (15, 16). A number of
genes associated with diabetes susceptibility loci regulate the
survival and/or functions of Tregs (e.g., CTLA4, IL-2, STAT5) (17–
19). Despite clear evidence of Treg influence on T1D development,
it remains controversial as to what the changes are in the Treg
population that actually contribute to the natural pathogenesis of
diabetes in NOD mice. Although some studies suggested a pri-
mary defect in the number and/or suppressor function of Tregs,
other studies pointed to the resistance of effector T cells to Treg-
mediated suppression as a possible mechanism of autoimmune
diabetes (20–25). Some of the discrepancies in the experimental
results may stem from the use of different markers (e.g., CD25 or
Foxp3), to identify and isolate the Treg population.
To better define the cellular and molecular basis of impaired Treg
function in diabetes, we examined populations of these cells
in young, prediabetic and aged, diabetic NOD mice expressing
a Foxp3GFP reporter that allows for unambiguous identification of
Tregs. We have found that compromised suppression mediated by
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Tregs was associated with decreased ability of conventional T cells
to upregulate Foxp3 and convert into iTregs in aging NOD mice.
We show that expression of connexin 43 (Cx43), a gap junction
protein and one of the TGF-b–inducible genes, progressively
declined in NOD mice progressing to diabetes. Gap junctions are
essential for transporting cAMP from Tregs into target T cells,
which initiates the genetic program of inhibiting T cell activation
(7, 26). In this study, we found that dysregulated expression of
Cx43 and alleviated cAMP signaling underlie progressive loss of
Treg suppressor function in NOD mice. This signaling defect and
impaired iTreg generation can be corrected by treatment of effector
T cells with TGF-b, which promotes upregulation of Cx43, and
RA, which regulates phosphorylation of connexin molecules and
intercellular communication through gap junctions. Our data
suggest that interactions that require cell contact and intercellular
communication are compromised in aged T cells in NOD mice.
Finally, using a novel reagent that inhibits a PDZ-based interac-
tion of Cx43 with the scaffolding protein zona occludens-1 (ZO-1),
we demonstrate that suppressor function could be augmented even
in Tregs isolated from NOD mice with diabetes.
Materials and Methods
Mice
NOD mice expressing Foxp3GFP reporter (NODGFP mice) were con-
structed as reported previously (27). A fragment of Foxp3 locus (lo-
cated on BAC clone RP23-446O15) was modified to express GFP
controlled by the Foxp3 regulatory sequences. Transgenic mice were
produced in Joslin Diabetes Center at Harvard University by injecting
NOD oocytes. Founders were identified by PCR of tail DNA.
All control mice were healthy, 2- to 4-wk-old NODGFP prediabetic
females referred to in this text as young mice, and diseased animals,
referred to as diabetic, were $20-wk-old females with diabetes (mice
with blood glucose levels ,120 mg/dl were considered healthy and those
with levels .300 mg/dl were considered diabetic). In some experiments,
age-matched Foxp3GFP reporter mice on the C57BL/6 (C57BL/6-Tg
[Foxp3-GFP]90Pkraj/J; Jackson Labs) genetic background (B6GFP
mice) were used as additional controls. The incidence rate of diabetes
in our colony was observed to be 85–90% for females and 15–20% for
males.
Diabetes was induced in 5- to 6-mo-old female B6GFP mice by strep-
tozotocin injections. Streptozotocin (Sigma-Aldrich) was dissolved in 0.1 M
citrate buffer (pH 4.5) and injected i.p. at a dose of 50 mg/kg/d for 5 d (28).
Mice were sacrificed at day 14 after initial injection when blood glucose
levels, measured for three consecutive days, were .350 mg/dl.
Full details of the study and all procedures performed on animals were
approved by the Institutional Animal Care and Use Committee of the
Georgia Regents University (approval #09-06-213) and complied with all
state, federal, and National Institutes of Health regulations.
Cell purification, flow-cytometry analysis, and cell sorting
Cells from peripheral (axillary, brachial, and inguinal), mesenteric, and
pancreatic lymph node (LN), spleens, and thymi were stained with Abs
specific for CD4, CD8, CD25, CD44, CD62L, CTLA4, GITR, pSTAT5,
Helios, and anti-rat CD2 (rCD2; BD, eBioscience, Biolegend), and analyzed
on a BD FACSCanto instrument. Cells were sorted on a MoFlo cell sorter
(Beckman Coulter; purity of all sorts exceeded 98%). Data were analyzed
using FlowJo (Tree Star).
Detection of p-STAT5
p-STAT5 was detected in CD4+ T cells isolated from pancreatic LNs from
young and old NODGFP mice and from B6GFP mice by intracellular
staining as described previously (29). LN cells were cultured in complete
media in the presence of IL-2 (10 ng/ml), stained with Abs specific for
CD4, CD8, and CD25, washed, fixed, and stained with p-STAT5 Ab
(pY694; BD).
Induction of Foxp3 expression
Sorted CD4+Foxp3GFP2 cells were activated with plate-bound anti-CD3
(10 mg/ml) and anti-CD28 (1 mg/ml) Abs (Biolegend) in the presence of
recombinant murine IL-2 (50 U/ml) and TGF-b (3 ng/ml) (both from
Peprotech) and monitored daily for GFP and Foxp3 upregulation by flow
cytometry and RT-PCR. Some wells contained RA (3 nM; Sigma-Aldrich).
This experiment was done at least five times.
RT-PCR
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) and con-
verted into cDNA using the Superscript III kit (Invitrogen). Gene ex-
pression studies were performed using quantitative real-time PCR and
TaqMan probes (Invitrogen). All data were normalized for b-actin ex-
pression, and expression differences were shown as relative expression.
Data were acquired with ABI7900HT instrument. All primers had been
used previously (27, 30).
Analysis of Foxp3 expression in single cells was done as described
previously. In brief, single cells were sorted from populations of CD4+
Foxp3GFP2 and Tregs expressing low and high levels of Foxp3 directly into
96-well PCR plates containing reverse transcription buffer, and cDNA
was synthesized. Foxp3 and b-actin transcripts were amplified by two
rounds of PCR using nested primers: Foxp3: first round 59-GCCTG-
CCACCTGGGATCAAT-39 and 59-CACAGATGGAGCCTTGGCCA-39
primers, second round 59-CACCCAGGAAAGACAGCAACC-39 and 59-
CTTCTCCTTTTCCAGCTCCAGC-39; b-actin: first round 59-GACATG-
GAGAAGATCTGGCACCA-39 and 59-CTCTTTGATGTCACGCACGATT-
TC-39 and second round 59-CCTTCTACAATGAGCTGCGTGTGGC-39
and 59-CATGAGGTAGTCTGTCAGGTCC-39 primers (30, 31).
Western blot
Sorted CD4+GFP2, CD4+GFP+, or CD4+CD252, CD4+CD25+ cells
were lysed directly in SDS-loading buffer and resolved on 12% poly-
acrylamide gel (5 3 104 cells/lane) and electrotransferred onto a PVDF
membrane (Millipore). Membranes were probed with Ab specific for
Foxp3 (1 mg/ml, eBio7979; eBioscience) as described previously
(27). For Smad2 and phospho-Smad2 detection, membranes were
probed overnight (4˚C) with the corresponding Abs (Cell Signaling
Technology). Images were scanned and analyzed using ImageQuant 5.2
software (GE).
Proliferation inhibition assay
Sorted CD4+Foxp3GFP+ cells were used as Tregs and CD4
+Foxp3GFP2
cells as responders as described previously (27). Responder cells (5 3
104/well) were incubated on a 96-well plate with irradiated splenocytes
(5 3 104/well, 3000 rad) and soluble anti-CD3ε Ab (5 mg/ml). Various
numbers of sorted CD4+Foxp3GFP+ cells (0.25–5 3 104/well) were
added. Cells were sorted using MoFlo sorter. Proliferation was assessed
by measurement of incorporated [3H]thymidine added (1mCi/well)
on the third day of a 4-d culture. For some assays, Gap26 (100 mM;
Anaspec) or aCT-1 (75 mM; American Peptide Company) peptides were
added to the wells.
Measurement of IFN-g
Flow-cytometry–sorted CD4+Foxp3GFP2 effector cells were mixed with
increasing proportions of sorted CD4+Foxp3GFP+ Tregs and irradiated
splenocytes, and stimulated with soluble anti-CD3ε Ab as described
earlier. Levels of IFN-g in the culture supernatant were measured in
triplicates with commercial ELISA kit (eBioscience).
STAT5b and Cx43 overexpression
Full-length cDNA encoding a constitutively active form of STAT5b
(STAT5b-CA; gift of Dr. A. Farrar, University of Minnesota) or Cx43 (Open
Biosystems) were cloned into retroviral vector pMx-IRES-rCD2 expressing
extracellular rat CD2 domain (gift of Dr. M. Iwashima, Loyola University).
Retroviral particles were prepared in Phoenix-Eco packaging cell line (gift
of Dr. G. Nolan, Stanford University), and culture media were used to
infect target cells. Sorted CD4+Foxp3GFP2 cells (5–10 3 104) were acti-
vated with anti-CD3 and anti-CD28 Abs and spin-infected with viral su-
pernatant. Transduction efficiency was assessed by staining for rat CD2
extracellular domain. Transduced cells in some wells were incubated with
IL-2/TGF-b or RA.
For retroviral transduction of Tregs, sorted Foxp3
GFP+ cells were acti-
vated overnight as described earlier in the presence of IL-2 (50 U/ml).
Cells were then infected with Cx43-encoding or control virus and further
expanded on anti-CD3/anti-CD28–coated plates in the presence of IL-2.
Two days later, rCD2 expression was assessed by flow cytometry. Tregs
expressing a high level of rCD2 (.90%) were used as suppressors, and
freshly sorted CD4+Foxp3GFP2 cells were used as effector cells in pro-
liferation inhibition assay.
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Calcein loading and dye transfer
iTregs and activated T cells were prepared from CD4
+ T cells expressing
transgenic TCR specific for pigeon cytochrome c antigenic peptide pre-
sented by I-Ab (32). iTregs were loaded with 0.5 mM calcein violet, AM
(Invitrogen) according to manufacturer’s instructions and stained with
anti–CD4-allophycocyanin. Responder cells stained with anti–CD4-PE
were mixed with iTregs and bone marrow–derived dendritic cells at
1:1:0.1 ratio in the presence (0.25 mM) or absence of antigenic peptide.
Cells were seeded in a round-bottom 96-well plate, and calcein transfer
into responder CD4-PE cells was recorded after 5 h using LSRII flow
cytometer (BD) equipped with violet laser.
Statistical analysis
All data are presented as the mean values 6 SD. The significance of
differences between samples or groups of mice was determined using
paired, one-tailed Student t test. Differences between samples with
p values #0.05 were considered significant. Statistical analysis was done
using Origin 9.0 software (OriginLab).
Results
The suppressor function but not cell numbers of Tregs decline in
aged NOD mice
To uncover what cellular and molecular characteristics are asso-
ciated with progression to disease, we have studied phenotypes and
an abundance of CD4+ T cell subsets in peripheral and pancreatic
LNs of young (2–4 wk) NOD mice with normal glucose levels
(120 mg/dl) and diabetic NOD mice ($20 wk) with overt diabetes
(.300 mg/dl glucose). To facilitate identification of Tregs, we have
produced Foxp3GFP reporter mice (NODGFP). A modified BAC
clone previously used to generate Foxp3GFP reporter mice in the
C57BL6 strain (B6GFP) was introduced into NOD oocytes
(Fig. 1A–D) (27). Thus, the generation of our reporter mice did
not involve backcrossing of transgenic founder animals onto an
NOD genetic background. Transgenic reporter and wild type NOD
mice had equivalent numbers, percentages, and cell-surface phe-
notypes of all T cell subsets, including CD4+CD25+ T cells, in
thymus, LNs, and spleen. Consistent with earlier reports, a nor-
mal, or even increased, proportion of Foxp3GFP+ T cells was ob-
served in NODGFP mice of every age, including young and
diabetic mice (Fig. 1E, 1F) (24). Moreover, we observed a mod-
erate increase of Tregs in peripheral and pancreatic LNs. Despite
stable proportions of Tregs, we observed phenotypic changes of
Treg populations: cells from diabetic mice expressed lower levels
of GITR, CTLA4, and Helios, but higher levels of CD39 and PD-1
(Fig. 1G and data not shown). Aged NODGFP mice had expanded
populations of activated CD44+CD62L2 conventional CD4+ T cells
in peripheral LNs including pancreatic LNs (Fig. 1H, 1I). We have
also observed enhanced proliferative responses of Foxp3GFP2 ef-
fector cells stimulated in vitro, which correlated with increased
blood glucose levels (Fig. 1J, 1K).
Because disease progression was not associated with declin-
ing proportions of Tregs, we checked the ability of these cells to
suppress the immune response. For that purpose, we examined
Tregs expressing low and high levels of Foxp3 from young and
diabetic NODGFP mice in a standard proliferation inhibition assay
and compared these mice with diabetes-resistant B6GFP mice. We
consistently observed decreased capacity of Tregs isolated from
diabetic animals to inhibit proliferation of activated, conventional
(CD4+Foxp3GFP2) Th cells from young NODGFP mice (Fig. 2A).
However, Tregs from both young and diabetic NOD
GFP mice had
lower suppressor capacity than corresponding cells from B6GFP
mice. In a reciprocal experiment, Tregs from young NOD
GFP mice
were able to significantly inhibit proliferation of effector CD4+
T cells from older, diabetic animals. Finally, proliferation inhibi-
tion was smallest when Tregs and responder cells were both iso-
lated from aged, diabetic mice (Fig. 2B). To examine whether
hyperglycemia could alter Treg functions, we have induced dia-
betes in 4- to 5-mo-old B6 mice by streptozotocin injection. This
experiment shows comparable inhibition of proliferation and
IFN-g production by cells isolated from normal and hyperglyce-
mic mice, demonstrating that observed differences in Treg sup-
pression are likely not caused by differences in blood glucose
levels (Supplemental Fig. 1A, 1B). Together, our data demonstrate
that functional, not quantitative, changes of Tregs are associated
with disease progression in NOD mice. Higher proportion of Tregs
from old NOD mice than from young and aged B6 mice is needed
to achieve the same level of suppression, suggesting that immune
environment permissive for autoimmune disease already exists
before overt diabetes.
Effector CD4+ T cells and Foxp3GFPlo Tregs from diabetic mice
have decreased ability to upregulate Foxp3 expression when
activated in the presence of IL-2 and TGF-b
We have routinely observed that a small, but consistent proportion
of sorted naive CD4+ T cells from B6GFP mice upregulated Foxp3
when activated in vitro without exogenous IL-2 and TGF-b (30).
In NOD mice, we noticed that a larger fraction of effector cells
from young NODGFP mice than from older mice upregulated
Foxp3 when cells were activated in vitro (Fig. 3A). This age-
dependent decline in the ability of effector T cells to upregulate
Foxp3, not seen in aging B6GFP mice, suggests reduced and de-
layed capacity to generate iTregs in aged NOD mice (Fig. 3B).
Consistent with our previous analysis of B6GFP reporter mice,
we examined whether the population of Tregs in NOD
GFP mice
is heterogeneous, with cells being differentially sensitive to Ag/
cytokine stimulation. To examine how Foxp3 is regulated in
T cell subsets in young and aged NODGFP mice, we activated
conventional CD4+Foxp32 cells and Foxp3lo and Foxp3hi Tregs
with plate-bound anti-CD3/anti-CD28 Abs without and in the
presence of TGF-b and IL-2 (33). A large proportion of Foxp3hi
Tregs, which constituted a majority of the Treg population, pre-
served a stable Treg phenotype in young and old NOD
GFP mice
when activated (Fig. 3C, 3D). In contrast, conventional Foxp32
cells and Foxp3lo Tregs from aged NOD
GFP mice have a decreased
ability to upregulate and/or maintain Foxp3 expression compared
with the respective populations from young mice. In particular, the
Foxp3lo subset in aged mice had an unstable Treg phenotype, and
only a small proportion of these cells was able to sustain Foxp3
expression when stimulated with anti-CD3/anti-CD28 Abs even in
the presence of TGF-b (Fig. 3D). Altogether, our results suggest
that CD4+ T cell populations, identified in previous reports as
precursors of pTregs, are most affected by the dysregulated ex-
pression of Foxp3 in aging NOD mice.
Dysregulated upregulation/expression of Foxp3 in aged NOD
mice is associated with decreased signaling through STAT5
and Smad2/3
To delineate molecular mechanisms of age-related weakening of
Treg suppression, we examined regulation of Foxp3 expression by
IL-2 and TGF-b. IL-2 and TGF-b are cytokines critical for gen-
eration and maintenance of peripheral Tregs (34). Previous studies
have shown that components of the IL-2 signaling pathway map to
diabetes susceptibility loci (19, 35, 36). Mutations of STAT5,
a component of the IL-2R signaling pathway, were associated with
impaired function of Tregs in NOD mice (18). Similarly, TGF-b,
acting through Smad2/3, was found to regulate genes controlling
Treg functions and insulin-specific Tregs (37, 38). Decreased ex-
pression and/or phosphorylation of STAT5 or Smad2/3 could
suggest impaired signaling by IL-2 and TGF-b receptors, and
The Journal of Immunology 5263












FIGURE 1. Analysis of T cell subsets in young and diabetic NOD mice expressing Foxp3GFP reporter transgene. (A and B) Flow-cytometry analysis of
cells from thymus (A) and peripheral LN (B) of young and diabetic mice. Dot plots show expression of CD4 and CD8 on the populations of total thymic and
LN cells (upper panels) and expression of CD25 and Foxp3GFP on gated CD4+ cells (lower panels). (C) Analysis of Foxp3 expression in single cells
expressing low and high levels of Foxp3 (left panel shows gating strategy used for cell sorting). Single cells were sorted onto 96-well plates, and b-actin
amplification was used to identify wells containing cells. (D) The Foxp3GFP transgene is expressed exclusively in cells expressing endogenous Foxp3.
Western blot (upper panels) and RT-PCR (lower panels) analysis of Foxp3 expression in total CD4+ T cells and CD4+Foxp3GFP2, CD4+Foxp3GFP+ subsets
sorted from NODGFP mice, and in total CD4+ T cells and CD4+CD252 and CD4+CD25+ subsets sorted from wild-type NOD mice. b-Actin was used to
normalize samples. (E) Expression of CD4 and Foxp3 in peripheral and pancreatic LNs in young and diabetic NOD mice. (F) Proportions of Foxp3GFP+ in
populations of gated CD4+ T cells isolated from peripheral and pancreatic LNs and pancreas of young and diabetic NOD mice. The absolute numbers of
cells isolated from peripheral, pancreatic LNs and from pancreas are shown as plot inserts. Cells isolated from inguinal, brachial, and axillary LNs were
combined for peripheral LN analysis. Individual young mice are represented by squares (N), and diabetic mice are represented by triangles (O). Mean
values and standard deviations are shown by bars. (G) Expression of endogenous Foxp3, CTLA4, GITR, and Helios in sorted populations of Foxp3GFP2
(solid line), Foxp3GFPlo (broken line), and Foxp3GFPhi (dotted line) cells. (H) Percentage of activated CD44+CD62L2 cells in the (Figure legend continues)
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explain decreased Treg suppression in aging NOD mice. To test
this hypothesis, we studied protein expression- and signaling-
induced phosphorylation of STAT5 or Smad2/3 in young and di-
abetic NOD mice.
As shown in Fig. 4A and 4C, T cells from peripheral and
pancreatic LNs of young and diabetic NODGFP mice express
similar levels of STAT5, but much lower levels of Smad2/3. When
activated in the presence of IL-2 and TGF-b, decreased levels of
STAT5 and Smad2/3 phosphorylation were found in T cells from
diabetic mice (Fig. 4B, 4D). When compared with B6GFP mice,
decreased STAT5 phosphorylation was found even in CD4+
T cells from young mice (Fig. 4B). A recent report demonstrated
that mice with a constitutively active form of STAT5 have more
Tregs (39). To determine whether increased STAT5 signaling pro-
motes Foxp3 upregulation, we transduced CD4+ T cells from
NODGFP and B6GFP mice with a retroviral vector expressing
a constitutively active STAT5 mutant (gift of Dr. M. Farrar) and
activated them in the presence of IL-2 and TGF-b (40). Enhanced
signaling mediated by STAT5 resulted in an increased proportion
of cells upregulating Foxp3 only in effector cells isolated from
B6GFP mice (Supplemental Fig. 2). Collectively, examining STAT5
and Smad2/3 shows that impaired signaling by IL-2 and TGF-b
likely contributes to age-dependent decrease of Treg functions in
diabetic NOD mice.
Decreased expression/upregulation of Cx43 in old NOD mice
underlies impaired suppressor function of Tregs
In an attempt to restore Foxp3 upregulation in T cells isolated from
diabetic NODGFP mice to the levels observed in young NODGFP
mice, we treated naive cells isolated from diabetic NODGFP mice
with RA. As shown in Fig. 5A, addition of RA to T cells activated
in the presence of IL-2 and TGF-b resulted in a significant in-
crease in the proportion of iTregs. Effector cells from both young
and diabetic NODGFP mice upregulated Foxp3 with the same ki-
netics and produced the same percentage of iTregs at the conclu-
sion of culture.
One of the TGF-b– and RA-induced genes essential for Treg
development, Foxp3 expression, and contact-dependent suppres-
sion is Cx43 (26, 41). This gene is not expressed in naive CD4+
T cells in steady-state mice, but it is expressed in cells with ac-
tivated phenotype and in Tregs, especially Treg subset expressing
low levels of Foxp3.
Cx43 is a major gap junction protein in T lymphocytes, and
intercellular transport of cAMP between activated Tregs and target
CD4+ T cells was shown to inhibit upregulation of CD69, IL-2
gene expression, and cellular proliferation (26). Coculture of tar-
get CD4+ T cells with Tregs loaded with a fluorescent dye, calcein,
demonstrated that inhibition of activation was proportional to the
magnitude of calcein transfer and was blocked by gap junction
inhibitors. To show that the level of Cx43 expression correlates
with gap junction activity, we compared dye transfer between
calcein-loaded, iTregs, and responder CD4
+ T cells isolated from
B6GFP mice harboring two, one, or no functional alleles of Cx43
gene in CD4+ T cells (41). To mimic natural interactions between
T cells and APCs, we used Tregs and responder cells expressing
transgenic TCR and activated with antigenic peptide presented by
bone marrow–derived dendritic cells. Fluorescence of responder
cells correlated with Cx43 expression, revealing that gap junction–
mediated transport depends on Cx43 expression (Fig. 5B). This
result is consistent with a report demonstrating intercellular trans-
port mediated by Cx43 recruited into immunological synapse (42).
To further examine Cx43 involvement in Treg suppression, we
have generated iTregs from Cx43-sufficient and -deficient CD4
+
T cells. iTreg-expressing natural levels of Cx43 proved to better
inhibit activation of Cx43-sufficient T cells (Fig. 5C). In summary,
previously published and current data show how levels of Cx43
regulate intercellular, gap junction–mediated transport and impact
Treg-mediated suppression.
To study how Cx43 could contribute to altered Treg function, we
examined its expression pattern in CD4+ T cells in young and
diabetic NOD mice. Analysis of CD4+ T cell subsets sorted di-
rectly from experimental mice established a baseline for Cx43
expression and revealed low expression in activated and Foxp3lo
Tregs in diabetic NOD
GFP mice (Fig. 5D). Moreover, Cx43 is up-
regulated to much higher levels only in activated and Tregs from
young, but not diabetic NODGFP mice, especially in the presence
of TGF-b and in the absence of RA (Fig. 5E, 5F).
Age-related changes in the Cx43 expression coincide with the
loss of Treg function and suggest that the Treg suppression mech-
anism that relies on generation and intercellular transfer of cAMP
might be progressively compromised in aging NODGFP mice (7).
To further elucidate this mechanism, we compared expression of
adenylyl cyclases and phosphodiesterase, enzymes that regulate
cAMP levels, in young and diabetic NODGFP mice (43). Fig. 6A
shows that expression of adenylyl cyclases 4, 7, and 9, major
gated population of CD4+Foxp3GFP2 T cells isolated from peripheral (upper plots) and pancreatic (lower plots) LNs of young (left panels) and diabetic
(right panels) NODGFP mice. Flow-cytometry plots show expression of CD44 and CD62L. (I) Percentage of activated cells in the gated population of CD4+
Foxp3GFP2 cells in the peripheral and pancreatic LNs. Individual young mice are represented by squares (N), and triangles (O) represent individual aged
mice. Mean6 SD are shown. (J) CD4+ cells from aged NOD mice have higher proliferative potential. [3H]Thymidine uptake of anti-CD3– and anti-CD28–
stimulated cells from young (light bar) and diabetic (dark bar) mice is shown. Cells were pulsed at day 3, and proliferation (cpm) was measured after 18 h.
Experiment was repeated at least three times. (K) Blood glucose level measured in individual young (N) (3–4 wk) and diabetic NODGFP mice (O)
($13 wk). Glucose levels in aged B6GFP mice ()) are shown for comparison. Asterisks denote statistical significance (*p , 0.05).
FIGURE 2. Tregs from aged NOD
GFP mice lose suppressor function. (A)
T cell proliferation inhibition assay with Tregs sorted from young and di-
abetic NODGFP mice. Circles, triangles, and diamonds represent Tregs from
young and diabetic NODGFP and B6GFP mice, respectively, expressing low
(d, ▴, ♦) and high (s, O, )) levels of Foxp3. Gating strategy to isolate
Tregs expressing low and high levels of Foxp3 is shown in Fig. 1C. CD4
+
Foxp3GFP2 responder cells were sorted from young NODGFP mice.
Asterisks denote data points statistically different (*p , 0.05) between
young and aged NODGFP mice. One of at least three independent experi-
ments is represented. (B) Conventional CD4+Foxp3GFP2 cells from dia-
betic NODGFP mice remain sensitive to suppression by Tregs from young
NODGFP mice and to a much lower extent by Tregs from diabetic mice.
Proliferation of CD4+Foxp3GFP2 responder cells sorted from diabetic
NODGFP mice is inhibited by Tregs expressing low (d, ▴) or high levels of
Foxp3 (s, O) sorted from young (y) (left panel) and diabetic (d) (right
panel) NODGFP mice. The experiment was repeated two times. Error bars
denote mean 6 SD. *p , 0.05.
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enzymes that increase intracellular cAMP concentration in T lym-
phocytes, are low in resting Tregs and are upregulated upon acti-
vation in Tregs isolated from young and diabetic NOD
GFP mice.
Despite lower expression of cyclases in activated Tregs from dia-
betic NODGFP mice, especially of adenylyl cyclase 7, all cyclases
are significantly upregulated when compared with unstimulated
Tregs. Expression of phosphodiesterase 3b, a major cAMP-de-
grading enzyme in Tregs, does not increase in cells from diabetic
NODGFP mice upon Treg activation (Fig. 6A) (44). Because tran-
scription of the phosphodiesterase gene is downregulated by
Foxp3, our data suggest that Foxp3 is still able to control tran-
scription of its target genes even in aging NODGFP mice. Alto-
gether, we conclude that, despite finding dysregulated expression
of one adenylyl cyclase, expression of enzymes that control bal-
ance between cAMP generation and hydrolysis does not consid-
erably change between young and old NODGFP mice. Thus, low
expression of Cx43 in diabetic NODGFP mice likely results in
decreased intercellular transport of cAMP, which could contribute
to decreased suppressor function of Tregs in these mice.
To test this hypothesis, we overexpressed Cx43 in expanded Tregs
in vitro. Tregs expressing higher levels of Cx43 were more efficient
in inhibiting proliferation and IFN-g production than the same
cells expressing only low levels of Cx43 (Fig. 6B, 6C). Increased
suppression of Tregs overexpressing Cx43 closely matches and
compensates for the reduction of suppression seen between Tregs
isolated from young and diabetic mice. Both inhibition of prolif-
eration and IFN-g production were abrogated by reagents that
restrict intercellular communication through gap junctions, a-gly-
cyrrhetinic acid, and connexin extracellular loop mimetic peptide
FIGURE 4. IL-2 and TGF-b signaling pathways are altered in diabetic
NODGFP mice. (A) Total STAT5 protein level in total CD4+ cells isolated from
young and diabetic NODGFP mice. (B) Phosphorylation of STAT5 was assessed
by flow cytometry in total CD4+ T cells isolated from pancreatic LNs of young
(solid line) and diabetic (broken line) NODGFP mice and control B6GFP mice
(dotted line) stimulated for 15 min in the presence of IL-2 (10 ng/ml). Filled
histogram shows staining with isotype-matched Ab. Percentages of positive
cells from each mouse are shown. (C and D) Expression of Smad2 (C) and
its phosphorylated form (D) in young and diabetic NODGFP mice. CD4+
Foxp3GFP2 cells sorted from pancreatic LNs were lysed directly or stimulated
with TGF-b (1 ng/ml) for 30 min and then lysed in SDS gel-loading buffer.
b-Actin was used as a control for equal loading. Bars represent comparison of
protein quantities. Experiment was repeated twice.
FIGURE 3. Stability and kinetics of Foxp3 upregulation in in vitro–activated CD4+ T cells isolated from young and diabetic NOD mice and aged B6 mice. (A)
The percentage of CD4+ T cells isolated from peripheral LNs of young (N) and diabetic (O) NODGFP mice and B6GFP mice ()) that upregulate Foxp3 upon
activation. Sorted CD4+Foxp3GFP2 cells were activated with plate-bound anti-CD3 and anti-CD28 Abs and analyzed after 3 d. Individual mice are represented by
squares, triangles, and diamonds, and mean6 SD are shown for each group of mice. (B) Kinetics of Foxp3 upregulation in CD4+ T cells isolated from young and
diabetic NODGFP and B6GFP mice. CD4+Foxp3GFP cells sorted from young (light gray) and diabetic (gray) NODGFP and B6GFP (dark gray) mice were activated with
plate-bound anti-CD3 and anti-CD28 Abs in the presence of IL-2 and TGF-b, and expression of Foxp3 was quantitated with TaqMan probes after 1, 2, or 3 d of
a culture. Experiment was repeated two times. (C and D) Stability of Foxp3 expression in Tregs from young (C) and diabetic (D) NOD
GFP mice. Sorted CD4+
Foxp3GFP2 (4 3 105 cells, upper row), Foxp3GFPlo (2.5 3 105 cells, middle row), and Foxp3GFPhi (2.5 3 105 cells, lower row) cells from young and diabetic mice
were stimulated in vitro with plate-bound anti-CD3 and anti-CD28 Abs in the absence (columns one and three) or in the presence of IL-2 (50 U/ml) and TGF-b
(3 ng/ml; columns two and four) and analyzed after 3 d. In vitro–stimulated cells proliferated and their numbers increased 1.6 6 0.4, 2.3 6 0.4, 1.7 6 0.4-fold for
CD4+Foxp3GFP2, Foxp3GFPlo, and Foxp3GFPhi cells stimulated with anti-CD3 and anti-CD28 in the absence of IL-2 and TGF-b, and increased 1.96 0.3, 3.16 0.2,
1.8 6 0.1-fold for the respective populations stimulated in the presence of cytokines. Gating strategy to isolate Foxp3GFP2, Foxp3GFPlo, and Foxp3GFPhi cells is
shown on Fig. 1C. Rectangles show gates used for sorting (solid lines) and cell populations that upregulated or downregulated Foxp3 expression (broken lines).
Numbers denote percentages of cells. Data from one experiment of three is shown. Asterisks denote statistical significance (*p , 0.05).
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(Gap26), further demonstrating that overexpression of Cx43
enhances Treg function by facilitating contact-dependent sup-
pression (Fig. 6D, 6E) (45, 46). In summary, both cell prolif-
eration and IFN-g production are affected by decreased or
increased function of Cx43 in Tregs, prompting a possibility that
Cx43-dependent mechanisms could be targeted to modulate
Treg suppression (3, 4).
Redistribution of Cx43 within plasma membrane that promotes
gap junction formation and intercellular transport improves
suppressor function of Tregs in aged NOD mice
Intercellular communication through gap junctions depends on
interaction of two connexons (hemichannels), which are hexamers
of Cx43 forming a transmembrane channel, each contributed by the
contacting cell (47). Cx43 assembled in gap junctions and in the
adjacent domain, called perinexus, is associated with the ZO-1
protein through its C terminus. Disrupting interactions between
Cx43 and ZO-1 increased the proportion of connexon hemi-
channels docked to gap junctions relative to connexons in the
perinexus, increased size of gap junction plaques, and facilitated
intercellular communication (48). Because ZO-1, as well as Cx43,
are expressed in Tregs upon activation, interactions between these
two proteins may control the extent of gap junction formation and
increase Treg suppression. To test this hypothesis, we disrupted
interaction between ZO-1 and Cx43 using peptide reagent that
mimics C terminus of Cx43 (49). This reagent, called aCT-1, is
engineered to enter cytoplasm and bind the PDZ2 domain of
ZO-1, competitively inhibiting its interaction with the C terminus
of Cx43. We measured inhibition of proliferation and IFN-g pro-
duction in the absence and presence of aCT-1 using responder and
Tregs isolated from normal B6 mice. As shown in Fig. 7A, aCT-1
increased intercellular communication between Treg and target
cells, shown by calcein transport. Addition of aCT-1 was asso-
ciated with increased suppressor function of Tregs as demonstrated
by proliferation inhibition assay and IFN-g production (Fig. 7B).
Tregs isolated from mice with Cx43 gene deleted in T cells were
not affected by presence of aCT-1 (Fig. 7C). Considering that
Cx43 expression is decreased in Tregs from diabetic NOD
GFP mice,
we reasoned that suppressor function could be augmented in these
cells by increasing proportion of Cx43 available to form gap
junctions. In fact, we consistently noticed that aCT-1 improved
suppressor function of Tregs isolated from peripheral and pancre-
atic LNs of young and diabetic NODGFP mice and streptozotocin-
treated B6 mice, as demonstrated by inhibition of proliferation and
FIGURE 5. Decreased suppression of Tregs in NOD mice is associated with altered expression of Foxp3 and Cx43. (A) Coordinated signaling of RA and
TGF-b enhances the ability of CD4+ T cells from diabetic NOD mice to upregulate Foxp3 expression in vitro. CD4+Foxp3GFP2 cells sorted from young
(solid line) and diabetic (broken line) NODGFP mice and control B6GFP mice (dotted line) were stimulated for 3 d with anti-CD3/anti-CD28 Abs in the
presence of IL-2 (50 U/ml) and TGF-b (3 ng/ml) (left panel) or IL-2, TGF-b, and RA (3 nM) (right panel). Representative plots from at least three
experiments with three to four mice each are shown. (B) Expression levels of Cx43 regulate intercellular communication between iTreg and target CD4
+
T cells. Histograms show calcein fluorescence of target CD4+ T cells expressing two, one, or no functional Cx43 gene alleles. Target CD4+ T cells were
activated with PCC50V54A (0.25 mM) antigenic peptide presented by Ab-expressing bone marrow–derived dendritic cells in the presence of calcein-loaded
iTregs. (C) Proliferation inhibition assay using Cx43-sufficient responder cells and Cx43-sufficient (diagonal lines) and -deficient (horizontal lines) iTregs and
Cx43-sufficient natural Tregs (crossed lines). Solid bar represents proliferation of T cells (Tc) in the absence of Tregs. Treg (abbreviated to Tr) and responder
T cells (Teff) were used in a ratio of 1:2 or 1:1. (D) Decreased expression of Cx43 in diabetic NOD
GFP mice. Cx43 expression levels were measured by
quantitative PCR in freshly sorted naive (CD442CD62L+Foxp3GFP2) and activated (CD44+CD62L2Foxp3GFP2, act) conventional CD4+ T cells and in
Tregs expressing low (Fp3
lo) and high (Fp3hi) levels of Foxp3. (E) Upregulation of Cx43 expression in sorted naive CD4+ T cells activated in vitro with plate-
bound anti-CD3/anti-CD28 Abs in the presence of IL-2, TGF-b, and RA. (F) Cx43 expression in sorted CD4+Foxp3GFP+ Tregs activated with anti-CD3/anti-
CD28 in the presence of IL-2 for 3 d. Representative experiment of three is shown. Quantitative PCR data were obtained with TaqMan probes. Western blot
analysis confirmed that Cx43 protein levels in CD4+ T cell subsets from B6 and NOD mice activated in vitro increased, especially in cells activated in the
presence of TGF-b (data not shown). Light gray bars in plots (D)–(F) represent cells isolated from young NODGFP mice, gray bars represent cells isolated
from diabetic NODGFP mice, and dark gray bars represent cells from B6GFP mice.
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IFN-g production (Fig. 7D–G, Supplemental Fig. 1C, D). In-
creased suppression of Tregs was most apparent when these cells
constituted a small fraction of all T cells (5–10%) in the assay,
close to the natural proportion of Tregs in the lymphocyte pop-
ulation. This new reagent enhances gap junction–mediated sup-
pression mechanism, and may allow for compensation of Treg
deficit without the need to correct the underlying molecular def-
icit, for example, decreased Cx43 upregulation in diabetic NOD
mice. The data presented open a possibility that Tregs, even in
diabetic mice, retain suppressive potential that could be unmasked
by treatments that compensate for decreased expression and
function of key molecules mediating Treg functions.
Discussion
To better understand molecular processes associated with dia-
betes development, we examined CD4+ T cell subsets using a new
Foxp3GFP reporter mouse, produced on a pure NOD genetic
background. This analysis suggests that, similar to C57BL6 mice,
the population of Tregs in NOD
GFP mice is heterogeneous with
regard to the level and stability of Foxp3 expression (30, 50). Our
study extends earlier reports that Treg function deteriorates in aged
NOD mice and identifies Tregs expressing low levels of Foxp3 and
conventional CD4+ T cells as cell populations that are mostly
affected by age-related dysregulation of Foxp3 expression (22,
51). This is consistent with the recent report that a significant
fraction (∼20%) of all Tregs may lose Foxp3 expression (16). Our
data suggest that loss and/or downregulation of Foxp3 expression
might be caused by impaired signaling by IL-2 and TGF-b as
demonstrated by decreased phosphorylation of STAT5 and Smad2
in aged mice, even in optimal concentration of both cytokines. IL-2
and TGF-b are major cytokines that support peripheral maintenance
of tTregs and generation of pTregs upon antigenic stimulation (34).
pTregs were specifically identified as suppressor cells protecting
NOD mice subject to immunotherapy with anti-CD3 Ab, and their
decreased generation in older NOD mice could be regarded as
a contributing factor for diabetes development (14). We have pre-
viously suggested that continuous upregulation and downregulation
of Foxp3 in conventional CD4+ T cells in response to self-Ags
could be an important mechanism of immune tolerance and,
based on current data, one could speculate that altered kinetics of
this process may impact immunoregulation in NOD mice (30).
The finding that Cx43, a molecule essential for Treg suppression
and regulated by TGF-b, is only weakly upregulated in activated
CD4+ T cells in NODGFP mice progressing to diabetes comple-
ments earlier studies that dysregulation of TGF-b–dependent
genes might be an important molecular feature of progression to
diabetes (38). Loss- and gain-of-function studies undertaken in
this article identify Cx43 as a molecule that directly mediates Treg
suppression. Moreover, this Cx43 dependence is not regulated by
Foxp3, which is consistent with previous reports that functional
features and transcriptional signature of Tregs are controlled by
Foxp3-dependent and -independent genes (27, 52). The outcome
of decreasing expression of TGF-b–dependent genes in the course
of progression to diabetes might be magnified in the case of Cx43
by developing hyperglycemia. Both expression of Cx43 and
transport through gap junctions are decreased by hyperglycemia
(53, 54). Thus, progression to clinical disease likely combines
FIGURE 6. Impact of cAMP production and in-
tercellular transport on the suppressor function of
Tregs. (A) Expression of adenylyl cyclases (Adcy)
4, 7, and 9 (A) and phosphodiesterase 3b (Pde3b)
was measured in freshly isolated conventional CD4+
Foxp3GFP2 (TC) or Tregs or in the same T cell pop-
ulations (actTc and actTreg) activated in vitro. Light
gray bars represent cells isolated from young
NODGFP mice, and gray bars represent cells from
diabetic NODGFP mice. Quantitative PCR was per-
formed using TaqMan assay. Experiment was re-
peated twice. (B and C) Enhanced expression of Cx43
improved tTreg suppression. Cx43 was overexpressed
in Tregs sorted from young (s) and diabetic (O)
NODGFP mice activated in vitro and used in the pro-
liferation inhibition (B) and IFN-g production assays
(C). Cells transduced with empty vector served as
a control (d, ▴). Transduction efficiency exceeded
90% as monitored by the expression of rat CD2 ex-
tracellular domain, which was part of the expression
vector. (D and E) Cx43 mimetic peptide (Gap26)
inhibited gap junction formation and decreased sup-
pressor function of Tregs isolated from young (♦) and
aged (▴) NODGFP mice. Proliferation of responder
T cells (D) and IFN-g production (E) was higher in the
presence of gap junction inhibitor peptide (Gap26).
All experiments were done twice with six repetitions
for each measurement. Asterisks denote statistical
significance (*p , 0.05).
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immunological and metabolic factors that form a positive feed-
back loop and amplify each other.
Expression of Foxp3 and Cx43 is greatly enhanced in activated
CD4+ T cells from aged NODGFP mice by RA, and in vitro gen-
eration of iTregs is restored to the level seen in young mice. This
outcome shows that coordinate signaling, known to use different
pathways, is able to compensate for the signal transduction deficit
observed in aged cells. In recent reports, RA was shown to inhibit
T1D progression, and our data demonstrate that one of the un-
derlying molecular mechanisms of its effect could be to com-
pensate for the age-dependent decline in the ability to upregulate
and maintain Foxp3 and Cx43 expression in Tregs (10, 11). A
recent report, however, shows that RA may also decrease specific
phosphorylations of Cx43 that lead to increases in intercellular
communication through gap junctions revealing complexity of
regulatory mechanisms acting directly at the protein level or in-
directly through regulating gene expression (55). This activity of
RA is most likely due to directly enhancing association between
Cx43 and protein phosphatase 2A, because it does not depend on
transcription or new protein synthesis. Altogether, the current and
previous reports extend our understanding of how RA regulates
Tregs suppression, especially in the context of diabetes develop-
ment. It also highlights how interactions between immune system
and environmental factors (e.g., diet) may promote or prevent
disease progression.
Intercellular communication mediated by gap junctions has been
proposed as an important mechanism of Treg suppression (7, 26).
iTregs generated in vitro from CD4
+ T cells isolated from B6 mice
that have two, one, or no functional Cx43 gene alleles have pro-
gressively lower suppression (41). In this study, by examining
Cx43 gene expression pattern in effector cells and Tregs directly
isolated from young (prediabetic) and diabetic mice, or activated
FIGURE 7. C-terminal Cx43 mimetic peptide
aCT-1 improves Treg-mediated suppression. (A) aCT-1
increases intercellular communication through gap
junctions. Histograms show calcein fluorescence in
target Cx43-deficient or -sufficient CD4+ T cells ex-
pressing transgenic receptor activated with antigenic
peptide PCC50V54A (0.25 mM) in the presence of
bone marrow–derived dendritic cells and calcein-
loaded iTregs in the presence (dotted lines) or absence
(solid lines) of aCT-1. (B) Proliferation inhibition and
IFN-g production in the absence and presence of aCT-1.
Tregs and responder cells were isolated from Cx43-
sufficient B6 mice. (C) aCT-1 does not enhance sup-
pression of Tregs isolated from B6 mice where Cx43
gene was deleted in T cells. Proliferation inhibition
assay in the presence or absence (horizontal lines) of
aCT-1. Cx43-sufficient (diagonal lines) and -deficient
(horizontal lines) Tregs were incubated with Cx43-suf-
ficient responder cells in a ratio of 1:2. Due to low
proportion of Tregs in mutant mice, only one ratio of
Treg/responder cells was tested. Solid bar represents
proliferation of responder cells in the absence of Tregs.
(D–G) Tregs isolated from peripheral (D and F) and
pancreatic (E and G) LNs of young (s, d) and aged
(O, ▴) NODGFP mice were used in the proliferation
inhibition assay (D and E) and to inhibit IFN-g pro-
duction (F and G) in the presence (s, O) or absence
(d, ▴) of aCT-1. One experiment of two is shown with
six repetitions of each well. Asterisks denote statistical
differences in cell proliferations between Tregs cultured
in the presence or absence of aCT-1 peptide.
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in vitro, we attempted to explain how intercellular communica-
tion, mediated by Cx43, may mechanistically contribute to im-
mune regulation of diabetes in NOD mice. We have introduced
a novel reagent, the Cx43 mimetic peptide aCT-1, to promote
Treg-mediated suppression. Distinct from Gap26, the other mi-
metic peptide used in this study that inhibits both hemichannels
and gap junction channels, aCT-1 selectively reduces hemi-
channel activity, whereas promoting gap junction plaque forma-
tion (48). This is achieved by a novel mechanism in which aCT-1
releases undocked hemichannels from ZO-1 PDZ2 tethering at the
plaque edge (i.e., the perinexus), prompting them to dock into gap
junctions, thereby resulting in a loss of hemichannel activity and
a complementary gain of gap junction function. Our results show
that aCT-1 serves as a new experimental tool demonstrating that
Tregs, even in diabetic, hyperglycemic mice, preserve Treg sup-
pressor capacity, which can be, at least partially, restored. It is also
notable that Cx43 hemichannels have key assignments in the
inflammatory response, acting as conduits for the release of pro-
inflammatory mediators such as ATP (56). Inhibition of hemi-
channel activity by promoting gap junction formation thus may
represent a further factor to consider in the maintenance of b cells.
Dysregulated expression of Cx43 in smooth muscle cells and al-
tered communication through gap junctions were reported in di-
abetes patients and were considered as a contributing factor in the
development of diabetes complications including vascular reti-
nopathy (54, 57). In phase II clinical testing, aCT-1 improves
healing of diabetic foot ulcers and venous leg ulcers—pathologic,
slow-healing wounds that are caught in chronic inflammatory
states (58). This report shows that Cx43 functions are compro-
mised in Tregs, directly involved in controlling immunological
mechanisms leading to the destruction of pancreatic islets. Ex-
ploiting these mechanisms further may lead to a better under-
standing of immune regulation in diabetes and to the development
of new therapies for diabetes and other autoimmune diseases. In
conclusion, we hope our report contributes to better understanding
of signaling pathways and individual molecules in regulating
immune suppression mediated by Tregs in NOD mice.
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